Background
==========

Temporomandibular joint disorder (TMD) is characterized by a set of symptoms related to the muscles and joints that reside between the mandibular condyle and the temporal bone. The most common symptoms are joint sounds, pain, and limited joint movement \[[@B1]\].

According to the NIDCR \[[@B2]\] (National Institute of Dental and Craniofacial Research), 5-12% of the population suffers or has suffered at some time from problems related to temporomandibular joint disorder (TMD) \[[@B3]\]. It is considered the most common cause of chronic pain in the orofacial region.

There are multiple factors that could cause or contribute to TMD disorder, including trauma, several types of arthritis, dental problems, autoimmune diseases, psychological and hormonal factors \[[@B4]\] and also commonly associated with other related symptoms in the head and neck \[[@B5]\].

Due to its etiological and symptomatic variety, it is assumed that a combination of factors related to environmental and/or nutritional stress could be an underlying cause of TMD \[[@B6]-[@B9]\]. As for genetic factors, studies of twins and familial segregation suggest that TMD is not a hereditary disease \[[@B10],[@B11]\]. Nevertheless, individuals are not equally susceptible to TMD, and different genetic variants can increase the predisposition to a particular development of the disorder \[[@B12]-[@B22]\].

TMD is a problem that affects women two times more than men and its causes are not completely known. Certain hormones can increase inherent genetic vulnerability to TMD, which explains the larger predisposition of women of reproductive age \[[@B4],[@B23]\]. The relationship between oestrogens and TMD has been studied previously \[[@B24],[@B25]\]; specifically, the polymorphisms of the receptor gene ER-α, *Pvu*II (rs2234693) and *Xba*I (rs9340799), seem to be related to several forms of osteoarthritis, including TMD \[[@B17],[@B19]\].

Folate metabolism can influences the final form of any growing tissue due not only to its participation in nucleic acid synthesis, but also to its known function in regulating DNA and protein methylation. Folate deficiency can cause central nervous system irritability, depression, weight loss, and anaemia. Nutritional deficiencies and, more specifically, abnormally low levels of vitamins B1, B6, B12, and/or folic acid are considered factors that perpetuate pain and myofascial dysfunction, and these deficiencies are frequent in cases of TMD mechanical stress \[[@B6]\].

Other mechanisms that have been related to TMD are factors related to psychopathological and pain perception, which can also be influenced by genetic variability. It has been described that the variants of a polymorphic region linked to gene SLC6A4 of the serotonin transporter (5-HTT gene-linked polymorphic region, 5-HTTLPR) \[[@B22]\] could be related to pain perception and temporomandibular disorder \[[@B18]\]. The 44 bp insertion/deletion polymorphism of the SLC6A4 gene has been extensively studied and frequently associated with the dopamine receptor gene DRD4; DRD4 variants have been associated with several clinical cases related to behavior, psychopathologies, and pain \[[@B17],[@B26],[@B27]\].

The following objective was to study the implication of 27 polymorphisms located on 17 genes and their relation with TMD. It has been designed under the hypothesis of that TMD is a multifactorial syndrome related to a critical period of human life that have a genetic and epigenetic basis both associated to folate metabolism, oxidative stress, hormones and neurotransmission.

Methods
=======

Study design
------------

A case-control study was designed to evaluate the impact of gene polymorphisms above described on TMD. A total of 229 individuals (69% women) were included at the study; 86 were TMD patients and 143 were healthy control subjects. The sample size was calculated using the prevalence of TMD and allele and genotypes frequencies of the polymorphism selected based on their known frequency in our population.

Patient recruitment
-------------------

Thirty five patients diagnosed with TMD who were admitted consecutively to private dental surgeries (\'Clínica Rincon\' and \'Clínica Dental Aneiros\' in Malaga, Spain), during a period of 8 months were included in this study. In addition, 556 volunteer students from Malaga University (57% female and 43% male) were invited to participate in the study. They answered a questionnaire for TMD (Table [1](#T1){ref-type="table"}) \[[@B28]\]. Ninety eight individuals responded affirmatively to four o more question of the questionnaire. So, they were invited to be clinically evaluated following the guidelines from The Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) \[[@B29]\] by a dentist who had experience in TMD evaluation. Fourteen subjects were excluded because they could not come to the physical examination and 33 had not clinical signs of TMD. Case group was 86 patients (35 previously diagnosed and 51 diagnosed volunteers), 64 women (74%), mean age 19.4 ± 2.9, and 22 men (26%) mean age 23.6 ± 4.1. Exclusion criteria for TMD patients were clinical history of traumatic injuries on head and neck, cranial anomalies of known or unknown etiology, inflammatory chronical disease component, mental retardation, drug dependence, and somatic or neurological illnesses.

###### 

Questionnaire form for TMD

  1\. Do you have difficulty or pain, or both, when opening your mouth, as for instance, when yawning?
  ------------------------------------------------------------------------------------------------------
  2\. Does your jaw get stuck, locked, or go out?
  3\. Do you have difficulty or pain, or both, when chewing, talking, or using your jaws?
  4\. Are you aware of noises in the jaw joints?
  5\. Do you have pain in or about the ears, temples, or cheeks?
  6\. Does your bite feel uncomfortable or unusual?
  7\. Do you have frequent headaches?
  8\. Have you had a recent injury to your head, neck, or jaw?
  9\. Have you previously been treated for a jaw joint problem? If so, when?

From *J Am Dent Assoc 1990, 120: 253-254*

The control group was built from the volunteers who did not answer affirmatively to any question. All participants were healthy, without any signs or symptoms of TMD and age matched to the TMD group. In short, control group consisted in 143 subjects, 94 women (66%), mean age 19,6 ± 3.3, and 49 men (34%), mean age 22,3 ± 4.1.

All the participants signed an informed consent form, and their personal data were recorded by interviewers. The study protocol was approved by Ethics Committee of Malaga University and conformed to the Helsinki Declaration.

Samples and DNA isolation method
--------------------------------

After obtaining informed consent, oral mucosa samples were collected from the 229 subjects. DNA isolation was performed using the salting out method, as described by Martinez et al. \[[@B30]\], applied to the oral mucosa.

Genotyping
----------

Three platforms were designed to perform the genotyping. Two of them for 20 Single Nucleotide Polymorphisms (SNP1, SNP2) and the third one for other polymorphisms of 7 gene variants (deletions, insertions, tandem repeat, null genotype). Primers were designed using the primer analysis software *Oligo*, version 4.0 and synthesized commercially. The primers sequences are shown in table [2](#T2){ref-type="table"}. To verify the validity and reliability of the techniques, the quality of each isolated polymorphism was checked in a simplex reaction.

###### 

Information of the polymorphisms included in the study

  Name         Reference        SNP/F   Location    A1   A2   Forward Primers              Reverse Primers            Minisequencing Primers       **Mult**.
  ------------ ---------------- ------- ----------- ---- ---- ---------------------------- -------------------------- ---------------------------- -----------
  **SHMT1**    rs1979276        SNP     3\'-UTR     A    G    CTGGCAGGGGATAAGTACCAG        GTCAACAGTTCCCCTTTGGA       CCGGAGGACCCCCAC              SNP1
               rs1979277        SNP     EXON        A    G    CTGGCAGGGGATAAGTACCAG        GTCAACAGTTCCCCTTTGGA       (T)31-GCCAGGCAGAGGGAAGA      SNP1
               rs643333         SNP     5\'-UTR     A    C    TGGACGCACATTTGTCCTAC         ATCAGAGAGCGCAGCCAAG        (T)24-ACCTGCAGAACTGACCC      SNP1
               rs638416         SNP     5\'-UTR     C    G    TGGACGCACATTTGTCCTAC         ATCAGAGAGCGCAGCCAAG        (T)91-GCAGGGCCTGTTTCTCC      SNP1
               rs3783           SNP     3\'-UTR     C    G    CTGGCAGGGGATAAGTACCAG        GTCAACAGTTCCCCTTTGGA       (T)115-GGGGTCCTCCGGCAG       SNP1
                                                                                                                                                   
  **TYMS**     rs2853542        SNP     5\'-UTR     C    G    GTGCCACACCCGTGGCTCC          GCCACAGGCATGGCGCGG         (T)84-GGGACGGAGGCAGGC        SNP1
               rs34489327       F       3\'-UTR     I    D    PET-CAAATCTGAGGGAGCTGAGT     CAGATAAGTGGCAGTACAGA                                    F
               rs34743033       F       5\'-UTR     2R   3R   VIC-GTGCCACACCCGTGGCTCC      GCCACAGGCATGGCGCGG                                      F
                                                                                                                                                   
  **TCN**      rs9606756        SNP     EXON        A    G    GGAGAAGGCCCTGGTAACG          CTTCCTTGGTCCCAGCCTG        (T)64-GGCTGTCCATCTCTGGTA     SNP1
               rs1801198        SNP     EXON        C    G    GGGAAAGAGACCCTGGAGC          GCTGGGAAATCATGAGAGC        (T)58-CCCAGTTCTGCCCCA        SNP2
                                                                                                                                                   
  **MTHFR**    rs1801131        SNP     EXON        A    C    CTTTGGGGAGCTGAAGGACTACTAC    CACTTTGTGACCATTCCGGTTTG    (T)71-AGGAGCTGACCAGTGAAG     SNP2
               rs1801133        SNP     EXON        C    T    GTGGTCTCTTCATCCCTCG          GACGGTGCGGTGAGAGTG         GAAGGTGTCTGCGGGAG            SNP2
                                                                                                                                                   
  **CBS**      rs5742905        SNP     EXON        C    T    GGTTCTTGGGTTTCTCATCC         CTCCGTCTGGTTCAGCTCC        (T)42-GCGCCCTCTGCAGATCA      SNP2
               cbs844ins68      F       INTR/EXON   S    L    6FAM-GTTGTTAACGGCGGTATTGG    GTTGTCTGCTCCGTCTGGTT                                    F
                                                                                                                                                   
  **ABCB1**    rs1045642        SNP     EXON        C    T    GCTGAGAACATTGCCTATGG         TAAGGGTGTGATTTGGTTGC       (T)34-GGTGTCACAGGAAGAGAT     SNP2
  **ATIC**     rs2372536        SNP     EXON        C    G    CCTAGATAGCTGTAAACCAC         GTAATCCCAAAACACAATC        (T)18-CCACAGCCTCCTCAACA      SNP1
  **BHMT**     rs3733890        SNP     EXON        A    G    TGTGAACTGCCACTTTGACC         ATGGGAATTCTGGGAGATCG       ATCAGGTGAGCTTTCAGT           SNP1
  **DHFR**     DHFR19bpdel      F       INTRON      \+   \-   ACGGTCGGGGTGGCCGACTC         6FAM-AAAAGGGGAATCCAGTCGG   F                            
  **GSTM1**    GSTM1del         F       EXON        \+   \-   PET-GAACTCCCTGAAAAGCTAAAGC   GTTGGGCTCAAATATACGGTGG     F                            
                                                                                                                                                   
  **MTHFD1**   rs2236225        SNP     EXON        C    T    CCCACTTTGAAGCAGGATTG         CATCCCAATTCCCCTGATG        (T)59-AACAAGCTTGAGTGCGATC    SNP1
  **MTR**      rs12749581       SNP     EXON        A    G    GCATTGACCATTACTACACC         TCCAAAGCCTTTTACACTCC       AATATGAAGATATTAGACAGG        SNP2
  **MTRR**     rs1801394        SNP     EXON        A    G    TTTCAGTTTCACTGTTACATGC       GTAACGGCTCTAACCTTATCG      (T)51-ACCACAGCTTGCTCACA      SNP1
  **RFC1**     rs1051266        SNP     EXON        A    G    TTCCAGGCACAGTGTCACC          CCGCGTGAAGTTCTTGTCG        (T)40-CCGGTCCTGGCGGC         SNP1
                                                                                                                                                   
                                                                                                                                                   
  **ESR1**     rs9340799        SNP     INTRON      A    G    AGGGTTATGTGGCAATGACG         CTGCACCAGAATATGTTACC       (T)~4~-AGACCCTGAGTGTGGTCT    SNP2
               rs2234693        SNP     INTRON      C    T    AGGGTTATGTGGCAATGACG         CTGCACCAGAATATGTTACC       (T)~28~-AGTTCCAAATGTCCCAGC   SNP2
                                                                                                                                                   
  **DRD4**     drd4-48bptr      F       EXON        S    L    NED-GCTGCTGCTCTACTGGGC       CCCGGCCGGTGATCTTGG                                      F
  **SLC6A4**   SCL6A45-HTTLPR   F       5-HTTLPR    S    L    VIC-GCGTTGCCGCTCTGAAGTC      GTGCCACCTAGACGCCAGG                                     F

SNP = Single Nucleotide Polimorphism; F = Fragment or Repeat; A1 = Allele 1; Allele2; MULT = Multiplex Reaction;SHMT1 = Serine Hydroxymethyltransferase1; TYMS = Thymidylate Synthetase; TCN = Transcobalamin II; MTHFR = 5,10-Methylenetetrahydrofolate Reductase; CBS = Cystathionine Beta-Synthase; ABCB1 = ATP-Binding Cassette B1; ATIC = 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase/IMP Cyclohydrolase; BHMT = Betaine-Homocysteine Methyltransferase; DHFR = Dihydrofolate Reductase; MTHFD1 = Methylenetetrahydrofolate Dehydrogenase 1; MTR = 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; MTRR = Methionine Synthase Reductase; RFC1 = Reduced Folate Carrier 1; ESR1 = Estrogen Receptor 1; DRD4 = Dopamine Receptor D4; SLC6A4 = Solute Carrier Family 6

SNPs
----

Genotyping of SNPs was performed by multiplex minisequencing preceded by multiplex PCR \[[@B31]\]. This technique consists of three steps:

1\) Amplification of regions flanking the SNPs by multiplex PCR; PCR reactions were performed in a volume of 10 μL with 100 ng of genomic DNA, 1×Amplitaq Gold ^®^Buffer (Applied Biosystems), MgCl~2~1,5 mM, dNTPs 0,2 mM, 1 unit of Amplitaq Gold^®^DNA Polymerase (Applied Biosystems) and Primer Mix (primer concentrations ranged between 0,1-0,6 μM). Amplification was achieved in a 2720 Thermal Cycler^®^(Applied Biosystems) and consisted of 94°C for 5 minutes, followed by 35 cycles for 30 s at 94°C, 30 s at 58°C; 30 s at 72°C and a final extension for 7 min at 72°C. PCR products were checked in a 2% agarose gel, stained with SYBR^®^Safe DNA gel stain (Invitrogen) which resulted in 100 to 400 bp sized bands. In order to eliminate the excess of primers and dNTPs, the PCR products were digested by an \'ExoCiAP\' mix consisting of 2 units/10 μL PCR *E. coli*exonuclease I (Exo I, Takara^®^) and 5 units/10 μLPCR alkaline phosphatase (CiAP, Takara^®^) incubated at 37°C for 60 minutes. The enzymes were afterwards inactivated by heating at 80°C for 20 minutes

2\) Multiplex mini-sequencing for each locus of the SNP multiplexes (SNP1, SNP2), a mini-sequencing primer with the 3\'-end adjacent to the target SNP was designed (see Table [2](#T2){ref-type="table"}) to anneal with the PCR product. A mini-sequencing reaction extends this primer, producing different products for each allele. We performed the reaction in a 11 μL volume with 4 μL purified PCR product and 6 μL of the mini-sequencing primers mix (2 pM/μL) and 1 μL of SNaPshot^®^multiplex kit (Applied Biosystems). The mini-sequencing conditions consisted of 40 cycles at 96°C-10 s; 50°C-7 s; 60°C-30 s. After that, we proceeded to purify the sample using 1 unit of *alkaline phosphatase*(Takara^®^) at 37°C for 1 hour and then at 80°C for 20 min.

3\) Analysis of mini-sequencing products by capillary electrophoresis: We mixed 4 μl of the purified mini-sequencing products with 10 μl of HiDi™ formamide and 0.2 *μ*l of GeneScan-120 LIZ size standard (Applied Biosystems) and denatured at 95°C for 5 minutes. The fluorescently labeled products were resolved by capillary electrophoresis on an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems). The DS02 matrix (Applied Biosystems) was used at full speed for 17 minutes with 8 seconds of injection. The resulting data were analyzed with GeneMapper™ 4.0 Software (Applied Biosystems).

Other polymorphisms
-------------------

To detect other polymorphisms different from SNPs (deletions, insertions, tandem repeat, null genotype), a multiplex PCR assay was performed under the following concentrations (in a volume of 10 μL): 100 ng of genomic DNA, 1× GoTaq^®^FlexiBuffer (Promega), MgCl~2~1,5 mM, dNTPs 0,2 mM, Primer Mix (primer concentrations ranged between 0,1-0,6 μM), Betaine 50 mM and 1 unit of Go Taq^®^Flexi DNA Polymerase (Promega). The labeled primers are shown in table [2](#T2){ref-type="table"}. Amplification was achieved in a 2720 Thermal Cycler^®^(Applied Biosystems) and consisted of 94°C for 5 minutes, followed by 35 cycles for 30 s at 94°C, 45 s at 58°C; 1 min at 72°C and a final extension for 7 min at 72°C. We mixed 4 μl of PCR products with 10 μl of HiDi™ formamide and 0.2 *μL*of GeneScan-600 LIZ size standard (Applied Biosystems) and denatured at 95°C for 5 minutes. The fluorescently labeled products were resolved by capillary electrophoresis on an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems). The DS33 matrix (Applied Biosystems) was used at full speed for 45 minutes with 5 seconds of injection. The sizes of the alleles were analyzed with GeneMapper Ver. 4.0 (Applied Biosystems) software.

Statistics
----------

All analyses were performed using Statistical Package for Social Sciences statistical software (SPSS v. 16.0 for Macintosh; SPSS Inc., Chicago, IL). To determine the differences in genotype and allelic frequency of each studied polymorphism between TMD patients and healthy subjects, a chi-square test was used. Any p value \< 0.05 was considered as a statistical difference. In those polymorphisms that shown significant difference in genotype, the risk between subjects with TMD and healthy controls was evaluated by Cochran\'s-Haenzel odds ratios with a 95% confidence interval using sex as confounding factor.

Results
=======

Genotyping was performed for the 229 individuals. The results are summarized in Table [3](#T3){ref-type="table"}. Not all of the samples were valid for all genotypes, because of that, the number of individuals can vary from one polymorphism to another.

###### 

Allele and genotypes frequencies in TMD and control groups

  GENE         REFERENCE     ALELLE   PATIENTS    CONTROLS                ODDS RATIOS                                                                                                        
  ------------ ------------- -------- ----------- ----------- ----------- ------------- ----------- ----------- ----------- ----------- ------------------ ------------ -------- ----------- -------
                                      **G1**      **G2**      **G3**      **A1/A2**     **G1**      **G2**      **G3**      **A1/A2**   **Χ^2^genotype**   **Allele**   **OD**   **95%CI**   **p**
                                                                                                                                                                                             
  **SHMT1**    rs1979276     A/G      7 (0,10)    36 (0,49)   30 (0,41)   0,34/0,66     24 (0,20)   54 (0,45)   41 (0,34)   0,43/0,57                                                        
               rs1979277     A/G      8 (0,11)    31 (0,44)   32 (0,45)   0,33/0,67     35 (0,34)   28 (0,27)   41 (0,39)   0,47/0,53   0,002              G            3,99     1,72-9,25   0,002
               rs643333      A/C      3 (0,04)    32 (0,43)   39 (0,53)   0,26/0,74     10 (0,08)   47 (0,39)   64 (0,53)   0,28/0,72   ns                              \-                   
               rs638416      C/G      19 (0,24)   39 (0,50)   20 (0,26)   0,49/0,51     12 (0,10)   50 (0,41)   60 (0,49)   0,30/0,70   0,001              C            2,80     1,51-5,21   0,013
               rs3783        C/G      1 (0,01)    27 (0,36)   46 (0,62)   0,20/0,80     2 (0,02)    33 (0,28)   85 (0,71)   0,15/0,85   ns                              \-                   
                                                                                                                                                                                             
  **TYMS**     rs2853542     C/G      55 (0,73)   20 (0,27)   0 (0,00)    0,87/0,13     96 (0,76)   30 (0,24)   0 (0,00)    0,88/0,12   ns                              \-                   
               rs34489327    DI       9 (0,13)    25 (0,35)   38 (0,53)   0,30/0,70     7 (0,08)    32 (0,34)   54 (0,58)   0,25/0,75   ns                              \-                   
               rs34743033    2R3R     12 (0,17)   36 (0,50)   24 (0,33)   0,42/0,58     10 (0,12)   55 (0,64)   21 (0,24)   0,44/0,56   ns                              \-                   
                                                                                                                                                                                             
  **TCN**      rs9606756     A/G      57 (0,75)   16 (0,21)   3 (0,04)    0,86/0,14     85 (0,73)   30 (0,26)   1 (0,01)    0,86/0,14   ns                              \-                   
               rs1801198     C/G      30 (0,38)   38 (0,49)   10 (0,13)   0,63/0,37     56 (0,46)   61 (0,50)   6 (0,05)    0,70/0,30   ns                              \-                   
                                                                                                                                                                                             
  **MTHFR**    rs1801131     A/C      44 (0,57)   25 (0,32)   8 (0,10)    0,73/0,27     64 (0,53)   47 (0,39)   10 (0,08)   0,72/0,28   ns                              \-                   
               rs1801133     C/T      27 (0,35)   37 (0,48)   13 (0,17)   0,59/0,41     43 (0,34)   62 (0,49)   22 (0,17)   0,58/0,42   ns                              \-                   
                                                                                                                                                                                             
  **CBS**      rs5742905     C/T      0 (0,00)    12 (0,18)   54 (0,82)   0,09/0,91     2 (0,02)    27 (0,25)   81 (0,74)   0,14/0,86   ns                              \-                   
               cbs844ins68   SL       59 (0,84)   11 (0,16)   0 (0,00)    0,92/0,08     68 (0,81)   14 (0,17)   2 (0,02)    0,89/0,11   ns                              \-                   
                                                                                                                                                                                             
  **ABCB1**    rs1045642     C/T      28 (0,36)   38 (0,49)   12 (0,15)   0,60/0,40     30 (0,24)   64 (0,51)   31 (0,25)   0,50/0,50   ns                              \-                   
  **ATIC**     rs2372536     C/G      23 (0,49)   18 (0,38)   6 (0,13)    0,68/0,32     44 (0,43)   42 (0,41)   17 (0,17)   0,63/0,37   ns                              \-                   
  **BHMT**     rs3733890     A/G      11 (0,15)   29 (0,40)   32 (0,44)   0,35/0,65     17 (0,14)   54 (0,45)   49 (0,41)   0,37/0,63   ns                              \-                   
  **DHFR**     DHFR19del     -+       22 (0,31)   31 (0,43)   19 (0,26)   0,52/0,48     29 (0,31)   48 (0,52)   16 (0,17)   0,57/0,43   ns                              \-                   
  **GSTM1**    GSTM1del      \-       17 (0,23)   56 (0,77)               0,62/0,38     39 (0,40)   58 (0,60)               0,70/0,30   0,015              null         2,21     1,24-4,36   0,030
  **MTHFD1**   rs2236225     C/T      7 (0,09)    47 (0,63)   21 (0,28)   0,41/0,59     28 (0,24)   70 (0,60)   18 (0,16)   0,54/0,46   0,011              T            3,09     1,27-7,50   0,016
  **MTR**      rs1805087     A/G      55 (0,71)   20 (0,26)   2 (0,03)    0,84/0,16     80 (0,63)   42 (0,33)   4 (0,03)    0,80/0,20   ns                              \-                   
  **MTRR**     rs1801394     A/G      28 (0,37)   37 (0,49)   11 (0,14)   0,61/0,39     29 (0,25)   54 (0,47)   33 (0,28)   0,48/0,52   0,046              A            2,35     1,10-5,00   
  **RFC1**     rs1051266     A/G      15 (0,20)   42 (0,55)   19 (0,25)   0,47/0,53     28 (0,23)   59 (0,49)   33 (0,28)   0,48/0,52   ns                              \-                   
                                                                                                                                                                                             
  **ESR1**     rs9340799     A/G      37 (0,48)   35 (0,45)   5 (0,06)    0,71          55 (0,43)   59 (0,46)   13 (0,10)   0,67/0,33   ns                              \-                   
               rs2234693     C/T      13 (0,17)   44 (0,56)   21 (0,27)   0,45          32 (0,25)   60 (0,48)   34 (0,27)   0,49/0,51   ns                              \-                   
                                                                                                                                                                                             
  **DRD4**     drd448bptr    SL       50 (0,96)   2 (0,04)    0 (0,00)    0,98          69 (0,87)   7 (0,09)    3 (0,04)    0,92        0,039              L            3,12     0,76-17,2   0,161
                                                                                                                                                                                             
  **SCL6A4**   5-HTTLPR      SL       20 (0,43)   16 (0,35)   10 (0,22)   0,61          31 (0,40)   32 (0,41)   15 (0,19)   0,60        ns                              \-                   

ns = no statistical difference

Serine Hidroximetil Transferase 1 gene (SHMT1)
----------------------------------------------

This enzyme catalyzes the reversible conversion of serine to glycine, transferring methyl groups to tetrahydrofolate (THF), which is transformed into 5,10-methylenetetrahydrofolate (5,10-CH2-THF). During cellular proliferation, this is the predominant pathway for pyrimidine synthesis (see Figure [1](#F1){ref-type="fig"}).

![**The Folate and methionine cycles**. Abreviations: 10f-THF: 10-formyltetrahydrofolate; 5,10-CH2-THF: 5,10-methylenetetrahydrofolate; 5,10-CH-THF: 5,10-methenyltetrahydrofolate; 5mTHF: 5-methyltetrahydrofolate; AICART: Aminoimidazolecarboxamide ribotide transformylase; ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/imp cyclohydrolase; BHMT: Betaine-homocysteine methyltransferase; CBS: Cystathionine beta-synthase; DHF: Dihydrofolate reductase; DNMT: S-adenosylmethionine-dependent methyltransferases; DNMT, DNA methyltransferase; FTD: 10-formyltetrahydrofolate dehydrogenase; FTS: 10-formyltetrahydrofolate synthase; GNMT: glycine N-methyltransferase; GST: Glutathione S-transferase; MAT: methionine adenosyltransferase; MTCH: 5,10-methylenetetrahydrofolate cyclohydrolase; MTD: Methylenetetrahydrofolate dehydrogenase; MTHFR: 5,10-methylenetetrahydrofolate reductase; MTR: 5-methyltetrahydrofolate-homocysteine S-methyltransferase; MTRR: Methionine synthase reductase; NE: nonenzymatic interconversion of THF; PGT: phosphoribosyl glycinamidetransformylase; SAH: S-adenosylhomocysteine; SAHH: S-adenosyl homocysteine hydrolase; SAM: S-adenosylmethionine; SHMT: Serine hydroxymethyltransferase; TCN2: Transcobalamin II; THF: tetrahydrofolate; TS: thymidylate synthase; TYMS: Thymidylate synthetase.](1471-2350-12-75-1){#F1}

From the four polymorphisms studied on the cytoplasmic SHMT1 in TMD patients, a significant increase was observed of the G allele of the polymorphism rs1979277 (Leu435Phe) when compared with controls (OR = 3.99; 95% CI 1.72, 9.25; p = 0,002). Regarding the polymorphism SHMT1 rs638416 of the promoter region (5\'-UTR), a very significant increase was observed of the C allele and the CC genotype in TMD patients (OR = 2.80; 95% CI 1.51, 5.21; p = 0,013). Both polymorphisms are not linked \[[@B32]\], so their frequencies can be measured independently as a risk factor for TMD.

Methylenetetrahydrofolate dehydrogenase 1 gene (MTHFD1)
-------------------------------------------------------

The MTHFD1 gene encodes a protein that has three distinct enzyme activities: 5,10-methylenetetrahydrofolate dehydrogenase, 5,10-methylenetetrahydrofolate cyclohydrolase, and 10-formyltetrahydrofolate-synthetase. Each of these activities catalyzes one of three interconversion reactions of one-carbon derivatives of THF, which are substrates for the synthesis of methionine, thymidylate and purines. The trifunctional enzymatic activity is conferred by two larger domains: a terminal amino portion with dehydrogenase and cyclohydrolase activities and a larger domain with synthetase activity.

The transition from G to A (rs2236225) in the MTHFD1 gene that results in an alteration of ARG-653-GLN is clinically associated with susceptibility to neural tube defects (NTDs) sensitive to folates \[[@B33]\]. In our study, we found statistical differences in the alleles and genotypes frequencies between TMD patients and healthy controls. The T allele was more frequent in TMD patients (OR = 3.09; 95% CI 1.27, 7.50; p = 0,016).

Glutathione S-transferase mu 1 (GSTM1) gene
-------------------------------------------

This gene encodes mu-class glutathione S-transferase. Its function is the detoxification of electrophilic compounds, including carcinogens, drugs, toxins, and products of oxidative stress, by the conjugation with glutathione.

The GSTM1-null polymorphism is a deletion of the GSTM1 gene. The null variant of this gene has been associated with an increase of cancer and male infertility \[[@B34],[@B35]\] possibly due to greater susceptibility to environmental toxins and carcinogens as well as an alteration in the toxicity and efficiency of certain substances.

Our study found a statistical increase (OR = 2.21; 95% CI 1.24, 4.36; p = 0.030) of the null variant in TMD patients compared to the control group.

Methionine Synthase Reductase (MTRR) gene
-----------------------------------------

MTRR is responsible for the regeneration of Methionine Synthase (MTR) by reductive methylation using SAM as a methyl donor.

The substitution of A by G (rs1801394) in the encoding region is translated in Ile22Met. The G allele produces an enzyme with less affinity for the substrate \[[@B36]\]. A statistical increase of the A allele (OR = 2.35; 95% CI 1.10, 5.00; p = 0.037) was observed in the TMD group.

D4 receptor of Dopamine (DRD4) gene
-----------------------------------

DRD4-48bptr is the 48-bp VNTR in exon 3 of the DRD4, which encodes the third intracellular receptor loop and presents between 2 to 11 repeats. According to the number of repetitions, we can characterize the polymorphism as the short allele S-DRD4 (2 to 5 repetitions) and the long allele L-DRD4 (6 or more repeats) \[[@B37]\]. It was observed statistical differences on genotype frequencies in both groups (p = 0,039), but no statistical increase (OR = 3.12; 95% IC 0.76, 17.26, p = 0.181) of the S-DRD4 allele was found in patient group. The LL genotype was not found in any of the individuals with TMD.

Discussion
==========

Temporomandibular disorder has been associated with psychological dysfunctions \[[@B38]\], and sexual dimorphism \[[@B24]\]. Its occurrence also appears to coincide with puberty \[[@B25]\]. Currently, controversy exists as to the importance of underlying genetic and environmental nutritional factors, such as vitamin intake \[[@B7]\]. The folate-methionine axis takes part in both factors. In this axis, there are several polymorphic variants of the enzymes involved that together with folate dietary intake determines the metabolism of the axis. Furthermore, the transfer of methyl groups to DNA and proteins is one of the limiting factors for the correct development of the proliferating tissues. Therefore the latter is key for the continuous tissue growth and epigenetic modifications.

This work studied the implication of 27 polymorphisms located on 17 genes and their relation with TMD. It has been designed under the hypothesis of that TMD is a multifactorial syndrome related to a critical period of human life that have a genetic and epigenetic basis \[[@B12]-[@B22]\]. The study of genes related to folate cycle is directly involved in the two ways: the genetic, by gene polymorphisms, and epigenetic by the nutritional habits because of the folate intake. Deficit of folate intake is known as the most prevalent vitamin deficit in human. The majority of the genes studied were related to folate metabolism even though there were others related to oxidative metabolism and hormonal and neurotransmission receptors. Of the17 genes studied of the folate cycle, 3 of them (SHMT, MTHFD, MTRR) showed significant associations with TMD. Significant changes in the allele and genotype frequencies between the TMD patients and controls were found.

SHMT catalyzes a reversible step of THF to 5,10-CH~2~-THF, which is a key substrate to obtain 5-methyl-THF and synthesize thymidylate. On the other hand, MTHFD1 provides the 5, 10CH~2~-THF substrate in addition to having a central role in the cycle due to its triple functionality. The 5-methyl-THF to methionine step is catalyzed by MTR in cooperation with TCN and MTRR, which are essential for the participation of vitamin B12 as a cofactor and the reactivation of MTR, respectively.

In our case, a higher significant frequency of the allele SHMT-rs1979277G was observed in TMD patients (0.67 vs 0.53). The Allele G has been related to higher levels of folates and homocysteine \[[@B39]\], this could mean that the enzyme activity is deviated to the THF and glycine synthesis versus to the serine and 5,10CH~3~THF substrate of the MTHFR which provide 5\'CH~3~THF needed to the methionine synthesis by mean of homocysteine. The increase of homocysteine, classified as an oxidant, could favour inflamatory process. However the effect of this polymorphism on enzyme activity is still controverted \[[@B39]\].

Statistical differences were also observed in allelic frequency of the C allele the SNP rs638416, in the promoter region of the SHMT gene. SHMT not only provides one-carbon units for thymidylate biosynthesis but also generates a pool of methylenetetrahydrofolate for SAM synthesis by means of serine synthesis. In addition, the SHMT gene has the capacity to sequester 5-methyl-THF and therefore inhibit the synthesis of methionine and SAM, which is the methyl donor for DNA and proteins \[[@B39]\]. Therefore, greater SHMT activity would produce higher 5-methyl-THF sequestration, which would reduce SAM synthesis. Cellular deficits of SAM could induce lesser methylation on the novo synthetized DNA on inflamatory tissues, which can take to higher gene expresión levels, generating a positive feedback on inflammation and pain.

TMD patients and healthy controls had very significantly different genotypic frequencies of the SNP rs2236225 of the MTHFD gene. The triple functionality of the MTHFD enzyme and the central role it plays in the folate cycle make it one of the key points for the balance of this metabolic route \[[@B24]\]. Therefore, it is not difficult to believe that any genetic alteration that affects its expression or activity would have consequences for methyl transfer and consequently on epigenesis.

The results of the present work show that the polymorphic variants SHMT-rs1979277, rs638416, and MTHFD1-rs2236225 found in the folate cycle were significantly associated with TMD. They coincided with a global decrease in the availability of methyl groups via a decrease of the substrate 5,10-CH~2~-THF (SHMT and MTHFD1), while the SNP MTRR-rs1801394 did not follow the same pattern. The wild allele A, predominant in TMD, which means greater efficiency in the pathway of homocysteine to methionine, has the same final effect of the variants of SHMT and MTHFD, an increase of THF levels.

TMD have been associated to oxidative stress of the temporomandibular joint \[[@B40]-[@B44]\]. Regarding GTSM1, we found a significant number of individuals with TMD (OD = 2.21; 95%CI 1.24, 4.35; p = 0.030) with the null variant of the gene. It has been published that oxidative stress, which leads to the production of NO and peroxynitrite, is harmful to DNA in response to the excessive mechanical overload, which in turn promotes synovial hyperplasia in the temporomandibular joint \[[@B40]\]. This suggests that a reduced detoxification capacity would make us more susceptible to TMD.

Previous studies on associations of TMD with alpha ESR1 polymorphisms have shown different results. One of them find a predisposition to TMD associated to ESR1 polymorphism in women \[[@B15]\] others find a relation between pain \[[@B17]\] or craniofacial morphology \[[@B19]\] in TMD women with ESR1 polymorphism, however other recent report does not find this association\[[@B12]\]. In the present study there were no statistical differences in their individualized allelic and genotypic frequencies or in the distinct haplotype combinations. However, a study on the association between these polymorphisms and the predisposition to TMD has recently been published and deepens the characterization of the diplotypes using novel mathematic algorithms\[[@B15]\], which we will take into account in future studies.

In contrast to others authors \[[@B18],[@B21]\], significant variations were not found in the frequencies of the 5-HTTLPR (serotonin-transporter-linked promoter region) polymorphism of the serotonin receptor gene SCL6A4. However, we found a significant variation in the 48-bp VNTR polymorphism of the DRD4 gene. This polymorphism has been associated with pain processes, such as fibromyalgia \[[@B35]\] and migraine \[[@B36]\].

Conclusions
===========

In this study we have found new associations of polymorphic genes, related to folates, SHMT, MTHFD and MTR, oxidative stress GSTM1 and neurotransmission DRD4, with TMD. Concluding that the emergence of TMD in the tissues involved in joint morphogenesis in the final phase of maturity may occur due to multiple factors. Among those factors, we have found genetic polymorphisms involving folate deficiency, psycho-physical stress and the oxidative metabolism in cellular proliferation during puberty. The novelty of the results obtained in this study should be confirmed and extended in subsequent work with larger populations.
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